P-063 - AN OPEN-LABEL, SINGLE-DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF INFIGRATINIB (BGJ398) IN SUBJECTS WITH MODERATE RENAL IMPAIRMENT AND IN MATCHED HEALTHY ADULTS.
X. Ge1, M. Reyes1, S. Guptha2, G. Atiee2, T. Marbury3, E. Fuentes4, K. Roupe2, S. Andrews2, S. Moran1, D. Martin1; 1QED Therapeutics Inc., San Francisco, CA, USA, 2Worldwide Clinical Trials, San Antonio, TX, USA, 3Orlando Clinical Research Center, Orlando, FL, USA, 4Clinical Pharmacology of Miami, Miami, FL, USA.